Prime Medicine has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $161 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Prime Medicine is raising $161,000,000.00 in new funding. About Prime Medicine: Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
To learn more about Prime Medicine, visit http://primemedicine.com/
Contact:
Keith Gottesdiener, President and Chief Executive Officer
617-564-0013
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.